These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12788168)

  • 21. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal BG; Marcus R; Brecher M; Ternberg J; Behm FG; Cantor A; Wharam M; Chauvenet A
    J Clin Oncol; 1991 Sep; 9(9):1591-8. PubMed ID: 1714950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
    Straus DJ; Myers J; Koziner B; Lee BJ; Clarkson BD
    Cancer Chemother Pharmacol; 1983; 11(2):80-5. PubMed ID: 6194913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
    Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
    Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
    Diehl V; Loeffler M; Pfreundschuh M; Ruehl U; Hasenclever D; Nisters-Backes H; Sieber M; Smith K; Tesch H; Geilen W
    Ann Oncol; 1995 Nov; 6(9):901-10. PubMed ID: 8624293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience.
    Chim CS; Kwong YL; Lie AK; Lee CK; Ho FC; Liang R
    Am J Hematol; 1999 Jul; 61(3):159-63. PubMed ID: 10398307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
    Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
    Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).
    Aleman BM; Girinsky T; van der Maazen RW; Strijk S; Meijnders P; Bortolus R; Olofsen-van Acht MJ; Lybeert ML; Lievens Y; Eghbali H; Noordijk EM; Tomsic R; Meerwaldt JH; Poortmans PM; Smit WG; Pinna A; Henry-Amar M; Raemaekers JM; ;
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1184-90. PubMed ID: 15936157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
    O'Reilly SE; Hoskins P; Klimo P; Connors JM
    Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy.
    Hodgson DC; Tsang RW; Pintilie M; Sun A; Wells W; Crump M; Gospodarowicz MK
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1374-81. PubMed ID: 14630276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience.
    Hunger SP; Link MP; Donaldson SS
    J Clin Oncol; 1994 Oct; 12(10):2160-6. PubMed ID: 7523608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.
    Klimo P; Connors JM
    J Clin Oncol; 1985 Sep; 3(9):1174-82. PubMed ID: 2411881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
    Klimo P; Connors JM
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience.
    Viviani S; Bonadonna G; Santoro A; Zanini M; Zucali R; Negretti E; Valagussa P
    Ann Oncol; 1991 Feb; 2 Suppl 2():55-62. PubMed ID: 1710921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
    Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
    J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.
    Hamilton VM; Norris C; Bunin N; Goldwein JW; Bunin GR; Lange B; Meadows AT
    J Pediatr Hematol Oncol; 2001 Feb; 23(2):84-8. PubMed ID: 11216711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
    Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
    J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.